Morningstar

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down ...

Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as ...
Morningstar

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis ...

VTAMA demonstrated early and consistent response rates in disease severity and itch improvements, measured by the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) and Peak ...
Insider Monkey

Organon & Co. (OGN) Announces American Academy of Dermatology’s Strong Recommendation for VTAMA Cream

Organon & Co. (NYSE:OGN) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, Organon & Co. (NYSE:OGN) announced that its VTAMA (tapinarof) cream, 1%, attained a strong recommendation ...
Nasdaq

OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis

Organon & Co. OGN recently announced findings from a pooled sub-analysis of its Phase 3 ADORING 1 and ADORING 2 pivotal trials assessing VTAMA (tapinarof) cream, 1%, in pediatric patients with ...